Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pat...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Ciara C., Moon, Dominic H., Kohn, Elise C., Lee, Jung-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937815/
https://www.ncbi.nlm.nih.gov/pubmed/24616882
http://dx.doi.org/10.3389/fonc.2014.00042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937815/
https://www.ncbi.nlm.nih.gov/pubmed/24616882
http://dx.doi.org/10.3389/fonc.2014.00042

Ejemplares similares